HealthLine. Bacteremia. Pneumonia 400,000 hospitalizations annually
|
|
- Corey Noah Simon
- 6 years ago
- Views:
Transcription
1 October 2017 THE OMNICARE HealthLine Focus on Pneumococcal Vaccines - by Allen Lefkovitz Streptococcus pneumoniae (aka pneumococcus) can cause serious and sometimes life-threatening infections. As outlined in the figure below, pneumococcal infections can range from basic ear and sinus infections to more serious infections such as pneumonia, bloodstream infections, and central nervous system infections (e.g., meningitis). More than 90 types of Streptococcus pneumoniae have been discovered; however, 10 of these are believed to be responsible for nearly two-thirds of invasive pneumococcal disease. According to the CDC, Vaccines are the best way to prevent pneumococcal disease In addition to ear and sinus infections, Pneumococcus can cause: Meningitis 3,000 to 6,000 cases annually Mortality rate: 8% children, 22% adults More than 12,000 cases annually Cause of 36% of adult communityacquired pneumonia (CAP) cases Bacteremia Pneumonia 400,000 hospitalizations annually Mortality rate: 20% (up to 60% in the elderly) Mortality rate: 5-7% (rate may be higher in the elderly) Mortality is highest among the elderly and those with underlying high risk medical conditions According to the Centers for Disease Control and Prevention (CDC), Pneumococcal disease, whether or not resistant to antibiotics, is a major public health problem. It is estimated that 30% of severe cases of pneumococcal infections are due to strains of S. pneumoniae that are fully resistant to one or more clinically relevant antibiotics. Cases of resistant pneumococcal pneumonia result in approximately 19,000 additional hospitalizations each year. Beyond the mortality associated with pneumococcal disease, disabilities such as deafness, brain damage, or paralysis of arms and/or legs are possible. In 1980 influenza and pneumonia were the 4th leading causes of death in the United States, but continued vaccine development and the introduction of routine pneumococcal vaccination for children produced a significant reduction in pneumococcal disease such that influenza and pneumonia have declined to the 8th leading cause of death. Continued on next page Inside This Issue 1-3 Focus on Pneumococcal Vaccines 4 Safe and Proper Administration of IM Vaccines: Part 2 4 Medications Associated with Taste Disturbances 5 New Drug Vabomere for Injection 5 New Generic Medications 6 HealthLine Quiz
2 Focus on Pneumococcal Vaccines, continued. In addition to advanced age (particularly age 80 years), significant risk factors for pneumococcal disease include: residing in a nursing home asplenia chronic heart disease smoking stroke chronic obstructive pulmonary disease diabetes immunodeficiency or use of immunosuppressants (e.g., prednisone 20 mg daily) Available Pneumococcal Vaccines In addition to promoting good hand hygiene, good oral hygiene, and smoking cessation, the CDC states that Vaccines are the best way to prevent pneumococcal disease. Research continues to develop a better pneumococcal vaccine and/or an oral vaccine, but two distinct pneumococcal vaccines are available currently. Pneumococcal vaccines are considered 60-75% effective against invasive pneumococcal disease in immunocompetent elderly. While a pneumococcal polysaccharide vaccine containing 23 antigens [Pneumovax, (PPSV23)] was first approved in 1983, the first pneumococcal conjugate vaccine [Prevnar, (PCV7)] was approved in However, in 2010 PCV7 was replaced with a formulation containing 13 antigens [Prevnar 13 (PCV13)]. Up to 50% and 90% of all invasive pneumococcal disease cases in the elderly are caused by strains that are covered by PCV13 and PPSV23, respectively. Beyond the number of antigens contained in each vaccine, polysaccharide vaccines and conjugate vaccines differ significantly in their immunological response. While capsular polysaccharide vaccines (e.g., PPSV23) do not induce a T cell immune response, conjugated vaccines (e.g., PCV13) do produce a T cell response, and therefore stimulate antibody response as well as priming the immune system for a memory response. For this reason, even though PPSV23 provides protection against 10 additional strains, PCV13 may be more effective against the strains these two vaccines have in common. Prior to late 2014 and in the absence of other high risk conditions, PPSV23 was the only pneumococcal vaccine routinely recommended for adults aged 65 years and older. Research about the use of PCV7 in children from 2000 through 2009 demonstrated 47,000 fewer hospitalizations per year in children; however, an even more significant finding was that childhood pneumococcal vaccination, possibly through herd immunity, resulted in 73,000 fewer hospitalizations per year for individuals who are 85 years of age and older. Additionally, the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) showed that PCV13 was 75% effective against invasive pneumococcal infections caused by strains within the vaccine and was 45.6% effective in preventing pneumococcal pneumonia. As a result of these findings, in August 2014, the Advisory Committee on Immunization Practices (ACIP) began to recommend the additional routine use of PCV13 in older adults. ACIP recommended that for immunocompetent adults 65 years and older who had not received either pneumococcal vaccine previously, PCV13 should be administered first followed by a dose of PPSV months later. But for those who had previously received PPSV23, vaccination with PCV13 should wait at least 1 year following the last dose of PPSV23. In order to simplify their recommendation and to align with Centers for Medicare and Medicaid Services (CMS) coverage regulations, in September 2015 ACIP published a change in their recommendation about the interval of time between vaccination with PCV13 and PPSV23. Since that time ACIP has recommended that regardless of the order in which they are given, pneumococcal vaccines should be given at least 1 year apart. Although determining which pneumococcal vaccine(s) an individual has received can be challenging, in cases where it is not known, it is considered best to vaccinate. However, with regard to PPSV23, revaccination (i.e., a second dose of PPSV23) is a practice that is generally not routinely supported by the CDC except in a couple of scenarios: A one-time revaccination is warranted if the individual was less than 65 years old when they received the first vaccination, and they are now 65 years or older and it has been at least 5 years since the first vaccination. Children and adults younger than 64 who are at high risk of serious pneumococcal disease (e.g., asplenia, chronic renal failure) or are immunocompromised such that their antibody titers are anticipated to rapidly decline, should receive a second dose at least 5 years after the first vaccination. Continued on next page THE OMNICARE HEALTHLINE OCTOBER 2017 References for all content available upon request. 2
3 Focus on Pneumococcal Vaccines, continued. The table below provides a summary of individuals that should receive PCV13 and/or PPSV23. Condition PCV13 PPSV23 Age 65 Years and Older Resides in LTC Facility Chronic Heart Disease (e.g., heart failure) Chronic Lung Disease Diabetes Cerbrospinal Fluid Leak Cochlear Implant Alcoholism/Liver Disease Cigarette Smoking PPSV23 revaccination 5 years after first dose Asplenia (e.g., sickle cell) HIV Infection Chronic Renal Failure Malignancies (e.g., leukemia) Iatrogenic Immunosuppression (e.g., corticosteroids, radiation) Post-organ Transplant Similar to PPSV23, adults who received PCV13 most commonly reported pain, redness, and swelling at the injection site (>50% of patients), limitation of movement of the injected arm, fatigue, headache, chills, decreased appetite, generalized muscle pain, and join pain. While co-administration with the annual influenza vaccine is often encouraged, adverse events are generally greater than if they are administered at different times. Unless otherwise inappropriate, acetaminophen or ibuprofen can be used to ease joint pain and to reduce fever associated with vaccination. With regard to precautions it should be noted that if a resident has evidence of a moderate or severe illness, vaccination should be delayed until their symptoms resolve. If a female resident of childbearing age is pregnant, pneumococcal vaccines should generally be avoided. And if a resident is allergic to diphtheriacontaining vaccines, PCV13 should be avoided as the antigens are linked to a non-toxic diphtheria protein. Utilization of Pneumococcal Vaccines In 1989, only 14% of older adults were vaccinated with PPSV23. According to the most recent CDC data from 2015, 63.6% of older Americans have received at least one pneumonia shot. In a recently published study examining vaccination trends in U.S. nursing homes between 2006 and 2014, researchers found that only 78.4% of nursing home residents were vaccinated with pneumococcal vaccine in When more closely examining the unvaccinated residents, it was found that 73% were due to the resident or their responsible party declining vaccination; however, for 16% there was no documented evidence that they were ever offered the vaccine. In addition to improving documentation that each and every resident is evaluated and offered appropriate pneumococcal vaccinations, efforts should be made to better educate patients and their representatives about their benefits. These ideas are supported by tag F883 (previously F334) in Appendix PP of the State Operations Manual Influenza and pneumococcal immunizations, which states facilities must continue to have policies and procedures in place that ensure each resident or their representative not only has an opportunity to refuse immunization, but also, each resident or their representative must receive education about the benefits and potential side effects of the immunization. Also, unlike with other vaccinations, F883 says that self-reported history of vaccination is only permissible for influenza or PPSV23 (unless state laws have more stringent requirements related to documentation). However, the allowance of self-reporting is not currently acceptable for PCV13, meaning that facilities must obtain written, dated records for evidence of vaccination. THE OMNICARE HEALTHLINE OCTOBER 2017 References for all content available upon request. 3
4 Medication Safety Safe and Proper Administration of Intramuscular Vaccines: Part 2 - by Allen Lefkovitz This month s medication safety article is part 2 to last month s article overviewing the safe and proper administration of intramuscular (IM) vaccines. As stated last month, three general principles that can help guide the provision of safe IM vaccinations can be summarized under the categories of Size, Site, and Technique. While Size and Site were covered in September, overall Technique will be covered this month. Guidance in both articles should be adjusted by the healthcare professional based upon the specific situation and patient criteria. #3: Technique Proper technique is summarized in the figure below and spans both before and after the injection is given. PREPARE INJECT COMPLETE The patient should be seated The vaccine administrator should be seated or kneeling Uncover the area, locating the thickest part of the deltoid Wearing gloves, wipe with alcohol and let dry Encourage patient to relax Insert the needle at a 90 angle to the skin in a smooth, controlled motion Depress the plunger Withdraw the needle swiftly, or If using a retractable needle, activate the device while in the patient s arm Activate the safety device immediately Immediately dispose of the needle and syringe in the sharps container, without crossing your body Press cotton or gauze and tape to patient Deglove and wash hands The Clinical Capsule Medications Associated with Taste Disturbances* - by Allen Lefkovitz Taste disturbance is an adverse effect that significantly impacts quality of life and can cause/worsen weight loss, malnutrition, and mood disturbances. Some commonly utilized medications that can be associated with taste disturbance are outlined below. Bitter Taste Metallic Taste Sweet Taste Acetazolamide Amphetamines Carbamazepine Dorzolamide Fluorouracil Isosorbide Metolazone Procainamide Risperidone Sulindac Allopurinol Captopril Clarithromycin Eszopiclone Lithium Metformin Methocarbamol Metronidazole Nifedipine Phenytoin Propafenone Sulindac Tetracycline *This is not an all-inclusive list of medications associated with taste disturbances. Captopril Fluorouracil Nifedipine Salty Taste Captopril Chlorhexidine Lithium Nifedipine THE OMNICARE HEALTHLINE OCTOBER 2017 References for all content available upon request. 4
5 NEW Drug Vabomere for Injection - by Dave Pregizer Brand Name (Generic Name) How Supplied Therapeutic Class Approved Indication Usual Dosing Select Drug Interactions Most Common Side Effects Miscellaneous Website Vabomere TM [VA boh mear] (meropenem and vaborbactam) [mer oh PEN em and va bor BAK tam] 2 gram single-dose vials for injection containing meropenem 1 gram and vaborbactam 1 gram as sterile powder for constitution. Combination carbapenem antibacterial with a beta-lactamase inhibitor. Treatment of complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria in patients 18 years and older. 4 grams IV infusion every 8 hours over 3 hours for up to 14 days for patients with an estimated glomerular filtration rate (egfr) 50 ml/min/1.73m 2. Administration with valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. Administration with probenecid is not recommended as it increases plasma concentrations of meropenem. Headache, phlebitis/infusion site reactions, and diarrhea Dosage adjustment is recommended with renal impairment. No dosage adjustment necessary with hepatic impairment. Only compatible with 0.9% Sodium Chloride NEW Generic Medications Generic Name Brand Name Date Generic Available Lanthanum Carbonate 500 mg, 750 mg, 1000 mg Chewable Tablets Fosrenol Chewable Tablet 8/30/17 Sevelamer 800 mg Tablets Renvela Tablet 8/21/17 Prasugrel 5 mg and 10 mg Tablets Effient Tablets 8/15/17 THE OMNICARE HEALTHLINE OCTOBER 2017 References for all content available upon request. 5
6 HealthLine Quiz by Steve Law 1. Which statement about pneumococcal disease is FALSE: a. Meningitis may be caused by a pneumococcal infection b. A significant risk factor for pneumococcal disease is a person residing in a nursing home c. It is the 4th leading cause of death in the United State d. An estimated 30% of severe cases of pneumococcal infections are due to strains of S. pneumoniae that are fully resistant to one or more clinically relevant antibiotics 2. If an adult is 65 years and older and has not received either pneumococcal vaccine previously, the PPSV23 vaccine should be administered before the PCV13 vaccine: a. True b. False 3. According to F883, nursing home residents can self-report that they have received the PCV13 vaccine: a. True b. False 4. The proper technique to administer an injection intramuscularly, is to insert the needle at a 45 degree angle to the skin: a. True b. False 5. Which statement concerning medications causing taste disturbances is TRUE: a. Lithium can cause a sweet taste b. Metformin can cause a salty taste c. Risperidone can cause a metallic taste d. Acetazolamide can cause a bitter taste 5. Which statement is FALSE about the new medication, Vabomere : a. It is administered as an IV infusion b. It is indicated for the treatment of complicated urinary tract infections c. Dosage adjustment is needed in patients with hepatic impairment d. Valproic acid concentrations may decrease in patients taking Vabomere *Please note, the HealthLine Quiz is designed to help readers retain information that is relevant to their care setting. It is not an approved source of continuing education credits for healthcare professionals. Editorial Board Allen L. Lefkovitz, PharmD, BCGP, FASCP Senior Editor Carrie Allen, PharmD, BCGP, BCPS, BCPP, CCHP Assistant Editor Costadina A. Costianis, PharmD, BCGP Beth A. Frey, PharmD, MPM Steve Law, PharmD, BCGP Terry O Shea, PharmD, BCGP David Pregizer, RPh Falak Thaker, PharmD, BSc Contributing Authors for This Issue Allen L. Lefkovitz, PharmD, BCGP, FASCP Senior Clinical Advisor, Clinical Geriatrics, CVS Health David Pregizer, RPh Consultant Pharmacist, HCR-Manorcare Steve Law, PharmD, BCGP Clinical Services Manager for Indiana; Omnicare Pharmacies in Indiana Answers to the HealthLine Quiz: 1) C 2) B 3) B 4) B 5) D 6) C THE OMNICARE HEALTHLINE OCTOBER 2017 References for all content available upon request. 6
HealthLine. Focus on Heart Failure Part 2: Treatment Considerations
December 2017 THE OMNICARE HealthLine Focus on Heart Failure Part 2: Treatment Considerations Several studies have demonstrated that a lack of using guideline-directed therapy is associated with increased
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationPneumococcal Vaccines. What s right for your clients?
Pneumococcal Vaccines What s right for your clients? Vaccines Available - Pneumovax 23 A pneumococcal polysaccharide vaccine that includes 23 purified capsular polysaccharide antigens Vaccines Available
More informationThe Role of the Pharmacist in Pneumococcal Vaccination
The Role of the Pharmacist in Pneumococcal Vaccination The Role of the Pharmacist in Pneumococcal Vaccination Miranda Wilhelm, PharmD Clinical Associate Professor Department of Pharmacy Practice Southern
More informationOREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine
OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine Revisions as of 2/24/10 Pneumovax 23 should not be given concurrently with Zostavax
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationFlu & Pneumonia Provider Toolkit
Flu & Pneumonia Provider Toolkit 2018-2019 ILQI1809.1 Molina Healthcare and Providers Work Together to Protect Members from Flu & Pneumonia Molina Healthcare of Illinois (Molina) is continuing efforts
More informationVaccines for Primary Care Pneumococcal, Shingles, Pertussis
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More information9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationNORTHEAST HOSPITAL CORPORATION
NORTHEAST HOSPITAL CORPORATION Title: Influenza and Pneumococcal Immunization Date Effective: 11/04 Date Revised: 7/08, 2/6/12, 3/15/13; 9/13/13 Date Reviewed: Joint Commission Chapter: Provision of Care,
More informationPneumococcal 13-valent Conjugate Vaccine Biological Page
Pneumococcal 13-valent Conjugate Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.291 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide
More informationcontinuing education for pharmacists
continuing education for pharmacists Pneumococcal Disease: Treatment and Prevention Volume XXXIV, No. 3 Donald L. Bennett, R.Ph., MBA, Clinical Assistant Professor, The Ohio State University College of
More informationExpanded Use of PCV13 & PPV23
Expanded Use of PCV13 & PPV23 Dr. Jim Kellner Professor & Head Department of Pediatrics University of Calgary & Calgary Zone, Alberta Health Services Jim.Kellner@ahs.ca Objectives Explain the differences
More informationPatient & Family Guide. Prevnar 13. (Pneumococcal Conjugate Vaccine) and Kidney Disease.
Patient & Family Guide 2018 Prevnar 13 (Pneumococcal Conjugate Vaccine) and Kidney Disease www.nshealth.ca Prevnar 13 (Pneumococcal Conjugate Vaccine) and Kidney Disease What is Prevnar 13? Prevnar 13
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationStreptococcus Pneumoniae
Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic
More informationPatient & Family Guide. Pneumovax 23. (Pneumococcal Vaccine Polyvalent) and Kidney Disease.
Patient & Family Guide 2018 Pneumovax 23 (Pneumococcal Vaccine Polyvalent) and Kidney Disease www.nshealth.ca Pneumovax 23 (Pneumococcal Vaccine Polyvalent) and Kidney Disease What is Pneumovax 23? Pneumovax
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationSeries of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)
UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal
More information16 November 2017 National Immunisation Advisory Committee Recommendations for the 2017/2018 Influenza Vaccination Campaign
16 November 2017 National Immunisation Advisory Committee Recommendations for the 2017/2018 Influenza Vaccination Campaign Please note the National Immunisation Advisory Committee (NIAC) has updated the
More informationUKnowledge. University of Kentucky
University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 207 PNEUMOCOCCAL CONJUGATE VACCINE 3 COVERAGE IN CHILDREN, HIGH-RISK ADULTS 9-64 YEARS OF AGE, AND ADULTS OVER 65
More informationAdult Immunization Update 2015
Adult Immunization Update 2015 Objectives Upon completion of this session, the pharmacist should be able to: Compare and contrast previous versions of the ACIP immunization schedules with the most recent
More informationVaccines They re not Just for Kids
Mid-Maryland Internal Medicine 187 Thomas Johnson Dr., Suite 4 Frederick, MD 21702 www.midmarylandinternalmedicine.com Vaccines They re not Just for Kids Getting immunized is a lifelong job. Vaccines are
More informationthe benefits and potential side effects of pneumococcal immunization; and
F883 483.80(d) Influenza and pneumococcal immunizations 483.80(d)(1) Influenza. The facility must develop policies and procedures to ensure that- (i) Before offering the influenza immunization, each resident
More informationTo view past issues, go to: The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
From the Texas Department of State Health Services Immunization Branch The goal of the Vaccine Advisory is to disseminate, in a timely manner, practical information related to vaccines, vaccine-preventable
More informationVACCINATIONS FOR OLDER PATIENTS
VACCINATIONS FOR OLDER PATIENTS Douglas Fronzaglia II, DO, MS LECOM Institute for Successful Aging Geriatric and Internal Medicine 2/26/2019 Objectives Incorporate current CDC guidelines into your practice
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationPneum It's Your Health.
Pneum It's Your Health. Protect yourself. Protect your family. Protect your school. 2 Copyright 2010. NEA Healthy Futures (formerly NEA Health Information Network). All rights reserved. WHAT What is Pneumococcal
More informationPolicy and Procedure Manual
Policy and Procedure Manual Medication Management MM.3-6 SUBJECT/TITLE: PURPOSE: DEFINITION: ADULT, INPATIENT PNEUMOCOCCAL AND SEASONAL INFLUENZA VACCINATION To ensure that adult inpatients who are candidates
More informationNEWS RELEASE FOR INFORMATION CONTACT: Tel [203] Tel [203]
NEWS RELEASE FOR INFORMATION CONTACT: Caroline Calderone Baisley Deborah C. Travers Director of Health Director of Family Health Tel [203] 622-7836 Tel [203] 622-3782 September 18, 2017 For Immediate Release
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Update on Adult Immunization Strategies: Understanding the Current Recommendations EDWARD A. DOMINGUEZ, MD, FACP, FIDSA Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical Center,
More informationINTRODUCTION --- COLLEGE IMMUNIZATIONS
INTRODUCTION --- COLLEGE IMMUNIZATIONS The Ohio Revised Coded (ORC) Section 1713.55 states that beginning with the academic year that commences on or after July 1, 2005, an institution of higher education
More informationHealthLine. Focus on Heart Failure, Part 1: Classifications and Causes
November 2017 THE OMNICARE HealthLine Focus on Heart Failure, Part 1: Classifications and Causes he American Heart Association defines heart failure (HF) as a chronic, progressive condition in which the
More informationChapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015
Chapter 16 16 PPV introduced for at risk 1996 PCV7 introduced for at risk 2002 and as routine 2008 PCV13 replaced PCV7 in 2010 NOTIFIABLE In some circumstances, advice in these guidelines may differ from
More informationThe Omnicare HealthLine
The Omnicare HealthLine Inside This Issue 1-3 Focus on the 2017 ADA Diabetes Guidelines 4 Dosing Considerations for Newer Oral Anticoagulants 5 Clinical Capsule: Adverse Effects of Select Antidiabetic
More informationKeeping up with immunizations for adults
MEDICAL GRAND ROUNDS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will vaccinate their patients according to guidelines from the US Centers for Disease Control and Prevention CRAIG NIELSEN, MD Associate Professor,
More informationPneumococcal Vaccines: Questions and Answers
Pneumococcal Vaccines: Questions and s Question 1 What is pneumococcal disease? What is pneumococcal disease? So pneumococcal disease is a group of diseases that are caused by a bacteria. Most of us are
More information2013 Adult Immunization Update. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
2013 Adult Immunization Update David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Adult Immunization Update Pertussis Vaccine Influenza Vaccine Zoster
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar February 2016 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationFrom the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care
April 2015 Issue From the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care Therapeutic Interchange Recently AlixaRx announced the therapeutic interchange (TI) program
More informationPatient Immunization FAQ Sheet
Patient Immunization FAQ Sheet Shingles Vaccine: Q: Who should get the shingles vaccine (Zostavax )? A: Anyone 60 years of age or should get the shingles (herpes zoster) vaccine. There is no maximum age
More informationThe Omnicare HealthLine
The Omnicare HealthLine Inside This Issue 1-4 Focus on Seasonal Influenza 2016-2017 5 The Vaccine Adverse Event Reporting System 6 Clinical Capsule: Antipsychotic Therapy for Parkinson s Psychosis 6 Regulatory
More informationAdult Immunization Rates
Adult Immunization Rates California Immunization Coalition Summit May 5, 2014 Eileen Yamada, MD, MPH California Department of Public Health Immunization Branch Adult Immunization Rates California Data
More informationNew Vaccine Schedules. Disclosure. Overview. Immunization Recommendations in Primary Care. Objectives Pharmacists. Objectives Pharmacy Technicians
Disclosure Immunization Recommendations in Primary Care I have nothing to disclose. Betsy Blake, PharmD, BCPS October 2017 Objectives Pharmacists Learning Objectives: At the completion of this activity,
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar July 2017 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationVaccines and Adults: Our Collective Challenge Webinar
Vaccines and Adults: Our Collective Challenge Webinar Questions 1. What documentation would a pediatrician need to immunize adult parents to avoid some risk since they are non-patients of the practice
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More informationVaccine Preventable Diseases Among Adults
Vaccine Preventable Diseases Among Adults Stephanie Borchardt, MPH, PhD Wisconsin Immunization Program Division of Public Health Wisconsin Department of Health Services November 17, 2016 At a Glance Burden
More informationCOUNTY OF MORRIS DEPARTMENT OF LAW & PUBLIC SAFETY OFFICE OF HEALTH MANAGEMENT
1 COUNTY OF MORRIS DEPARTMENT OF LAW & PUBLIC SAFETY OFFICE OF HEALTH MANAGEMENT P.O. Box 900 Morristown, NJ 07963 (973) 631-5485 (973) 631-5490 Fax www.morrishealth.org 2012-2013 Influenza Season FREQUENTLY
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 6 To provide guidelines for administering immunizations. PURPOSE POLICY Immunizations are to be administered to all patients in accordance with the North Carolina Immunization Regulations and
More informationRecommended Vaccinations for Patients with Chronic Lung Disease RORY JOHNSON, PHARM.D., AE C ASSISTANT PROFESSOR UNIVERSITY OF MONTANA
Recommended Vaccinations for Patients with Chronic Lung Disease RORY JOHNSON, PHARM.D., AE C ASSISTANT PROFESSOR UNIVERSITY OF MONTANA Disclosures Nothing to Disclose Learning Objectives At the conclusion
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)
August 2011 Pneumococcal Disease, Invasive (IPD) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) Case Definition August
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE
Kenneth McCall, BSPharm, PharmD Associate Professor UNE Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize each of the CDC recommended flu vaccines
More informationSusan J. Rehm, MD, FACP, FIDSA Department of Infectious Disease Cleveland Clinic Cleveland, OH
Improving Adult Vaccination Practices Preventing Pneumococcal Disease in Your High-Risk and Older Patients Susan J. Rehm, MD, FACP, FIDSA Department of Infectious Disease Cleveland Clinic Cleveland, OH
More informationRxVaccinate. Support. Objectives. Disclosures 7/8/2013. Pneumococcal Immunization Update
RxVaccinate Pneumococcal Immunization Update Stephan L. Foster, Pharm.D., FAPhA, FNAP Professor and Vice-Chair College of Pharmacy University of Tennessee Health Science Center, Memphis, TN Liaison Member,
More informationTable 1 23 Pneumococcal Capsular Types Included in PNEUMOVAX 23
PRODUCT INFORMATION NAME OF THE MEDICINE: PNEUMOVAX 23 (pneumococcal vaccine, polyvalent, MSD) DESCRIPTION: PNEUMOVAX 23 (Pneumococcal Vaccine, Polyvalent, MSD), is a sterile, liquid vaccine for intramuscular
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IP Solution for injection 0.5-mL single dose vials and prefilled syringes BRAND NAME: PNEUMOVAX 23 SUMMARY OF PRODUCT CHARACTERISTICS
More information301 W. Alder, Missoula, MT or
301 W. Alder, Missoula, MT 59802 406-258-4745 or 406-258-3363 Routine Immunizations are available on a walk-in basis: Mondays, Tuesdays, Thursdays, and Fridays from 9:00am to 4:30pm Wednesdays, 10:00am-4:30pm
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More information3/10/2017. Overview N.J.A.C. 8:57-6. Purpose of N.J.A.C. 8:57-6. New Jersey Higher Education Immunization Requirements
N.J.A.C. 8:57-6 New Jersey Higher Education Immunization Requirements Jenish Sudhakaran, MPH Population Assessment Coordinator Vaccine Preventable Disease Program New Jersey Department of Health NJCHA
More informationH1N1 Vaccine Administration Manual for Paramedics
H1N1 Vaccine Administration Manual for Paramedics TABLE OF CONTENTS I. Introduction II. Policy and Procedure for Administering Medications A. Intradermal B. Intramuscular C. Subcutaneous III. Pictorial
More informationHow to create a successful vaccine program
How to create a successful vaccine program Nothing to disclose and no conflicts of interest Vaccine Overview Vaccine Guidelines Purchasing: Supply, Manufacturers, Storage, Returns Reimbursement Codes
More informationThe Omnicare HealthLine
The Omnicare HealthLine Inside This Issue 1-3 Focus on Seizure Disorder in Older Adults: Part 1 4 Entresto is Contraindicated with ACE Inhibitors 4 Increased Risk of Bladder Cancer with Pioglitazone- Containing
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationVaccine Information Statement: PEDIATRIC VACCINES (Multiple)
Vaccine Information Statement: PEDIATRIC VACCINES (Multiple) 1. Your Baby s First Vaccines: What You Need to Know Babies get six vaccines between birth and 6 months of age. These vaccines protect your
More informationPoint/Counterpoint. Mia A. Taormina, DO, FACOI MarkAlain Dery, DO, FACOI
Point/Counterpoint Mia A. Taormina, DO, FACOI MarkAlain Dery, DO, FACOI It s Influenza Season A couple in their 40s comes to your clinic in early August and asks about influenza vaccine. It is being offered
More informationGetting national guidelines into practice: It takes more than education
Getting national guidelines into practice: It takes more than education AI Collaborative Group 2 September 12, 2017 Lynette M. Wachholz, MN, ARNP, CPHQ Email: lwachholz@everettclinic.com The Everett Clinic
More informationDiabetes and Influenza
Your Comprehensive Guide to The Flu Season Investigate. InFORM. InSPIRE. winter 2017 Diabetes and Influenza www.diabeteshealth.com In This Issue INVESTIgate. INFORM. INSPIRE. COVER STORY 4 Diabetes and
More information7/13/2016. Immunization Update Disclosures. Objectives. No financial disclosures to report
Immunization Update 2016 Courtney A. Robertson, PharmD Clinical Assistant Professor University of Louisiana at Monroe School of Pharmacy Disclosures No financial disclosures to report Objectives Pharmacists
More information4/7/13. Vaccinations for Adults and Adolescents. Effect of Full Use of Adult Immunizations. General Vaccine Information
Vaccinations for Adults and Adolescents Nicholas A. Daniels, MD MPH Department of Medicine Professor of Clinical Medicine Declaration of full disclosure: No conflict of interest 2 Effect of Full Use of
More informationIf you have any concerns about being given this vaccine, ask your doctor or pharmacist.
PNEUMOVAX 23 Pneumococcal Vaccine Single Dose Vial/Pre-filled Syringe What is in this leaflet This leaflet answers some common questions about PNEUMOVAX 23. It does not contain all the available information.
More informationThe Omnicare HealthLine
The Omnicare HealthLine Inside This Issue 1-3 Updated Focus on Adverse Drug Events 4 Methotrexate Safety Reminders 5 Clinical Capsule: Drug Interactions with Oral Quinolones 5 Regulatory Recap 6 New Drug
More informationJon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health
Jon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health University of Wisconsin School of Medicine and Public Health Grand Rounds September
More information10/16/2018. Be Discuss. Describe. Discuss. Discuss 2018 ADULT IMMUNIZATION SCHEDULE INFLUENZA ADULT IMMUNIZATION UPDATE TRAINING OBJECTIVES FLUMIST
ADULT IMMUNIZATION UPDATE NORTH DAKOTA ACADEMY OF FAMILY PHYSICIANS NOVEMBER 10, 2018 Be Discuss Upon completion of the adult immunization training, participants will be able to: Discuss the general adult
More informationCall-to-Action: Recognizing the Burden of Vaccine- Preventable Diseases
Call-to-Action: Recognizing the Burden of Vaccine- Preventable Diseases Burden of Vaccine-Preventable Diseases Each Year 200,000 hospitalizations due to influenza As many as 36,000 deaths 29,100 cases
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationLana Hudanick RN, BSN Public Health Consultant Nurse Bureau of Immunization Assessment and Assurance Missouri Department of Health and Senior
Lana Hudanick RN, BSN Public Health Consultant Nurse Bureau of Immunization Assessment and Assurance Missouri Department of Health and Senior Services Identify the appropriate vaccines and the Advisory
More informationPNEUMOVAX 23 pneumococcal vaccine, polyvalent solution for injection
PRODUCT INFORMATION PNEUMOVAX 23 pneumococcal vaccine, polyvalent solution for injection NAME OF THE MEDICINE PNEUMOVAX 23 (pneumococcal vaccine, polyvalent) DESCRIPTION PNEUMOVAX 23 (Pneumococcal Vaccine
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationEvaluating Awareness of Pneumococcal Vaccination Among Adults 65 Years Old and Above Attending a SingHealth Polyclinic A Community Health Study
Evaluating Awareness of Pneumococcal Vaccination Among Adults 65 Years Old and Above Attending a SingHealth Polyclinic A Community Health Study Goh Zhaojing and Suriya Prakaash SingHealth Family Medicine
More informationModule 7: Case Discussion and Administration Technique
: Case Discussion and Administration Technique Miranda Wilhelm, Pharm.D. Clinical Associate Professor Department of Pharmacy Practice Southern Illinois University Edwardsville, School of Pharmacy 1 Disclosure
More informationImmunizations Offered
Immunizations Offered Most vaccines commercially available in the United States are available at the health clinic. A partial list of available vaccines follows. For more information about specific vaccines
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations
More informationThe Omnicare HealthLine
The Omnicare HealthLine Inside This Issue 1-3 Focus on COPD Exacerbation: Part 1 4 Boxed Warning for Opioids and Benzodiazepines 5 Clinical Capsule: COPD Beyond Bronchodilators 5 Regulatory Recap 6 New
More informationPreteen and teen vaccines: what to do with the recent recommendations
Preteen and teen vaccines: what to do with the recent recommendations MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Continuing Education The Illinois Chapter, American Academy
More informationChildhood Immunization Status
emeasure Title emeasure Identifier (Measure Authoring Tool) Childhood Immunization Status 117 emeasure Version number 5.1.000 NQF Number 0038 GUID b2802b7a-3580-4be8-9458- 921aea62b78c Measurement Period
More informationAdult Immunization Update. Presenter: Amanda Ingemi, PharmD, BCPS
Adult Immunization Update Presenter: Amanda Ingemi, PharmD, BCPS Objectives Describe how vaccines teach the body to fight infections. List vaccines available for adults and the indications. Describe the
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationTDCJ OFFENDER IMMUNIZATION GUIDELINES
TDCJ OFFENDER IMMUNIZATION GUIDELINES B-14.07 Immunizations Attachment A VACCINE WHO GETS IT * WHEN THEY GET IT DOSE/ROUTE HPV Vaccine Females age 9 to 26 years if not previously vaccinated. On Intake
More informationInfluenza Outbreaks. An Overview for Pharmacists Prescribing Antiviral Medications
Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral Medications Learning Objectives 1. Understand the
More informationNew Jersey Dept. of Health and Senior Services Public Information. Date: September 22, 2009 Time: 12:00 AM. H1N1 Vaccination Program
2009 H1N1 INFLUENZA New Jersey Dept. of Health and Senior Services Public Information Date: September 22, 2009 Time: 12:00 AM H1N1 Vaccination Program 1. What is novel H1N1 (swine flu)? Novel H1N1 (referred
More informationImmunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H.
Immunizations to Reduce Disease H. Keipp Talbot, M.D., M.P.H. Vanderbilt University School of Medicine 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding
More information